Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was downgraded by investment analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research note issued on Monday, July 31st. They currently have a $6.74 price objective on the biotechnology company’s stock. Vetr‘s price objective would indicate a potential upside of 10.49% from the company’s current price.
AUPH has been the subject of a number of other reports. Zacks Investment Research cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. HC Wainwright decreased their target price on Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, May 18th. Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, April 21st. BidaskClub cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, FBR & Co reaffirmed an “outperform” rating on shares of Aurinia Pharmaceuticals in a research note on Tuesday, April 11th. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $9.72.
Aurinia Pharmaceuticals (AUPH) opened at 6.10 on Monday. Aurinia Pharmaceuticals has a 52 week low of $1.88 and a 52 week high of $10.54. The stock has a 50 day moving average price of $6.31 and a 200 day moving average price of $6.27. The stock’s market capitalization is $509.26 million.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.10. The firm had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%. Equities analysts forecast that Aurinia Pharmaceuticals will post ($0.82) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Aurinia Pharmaceuticals Inc (AUPH) Rating Lowered to Buy at Vetr Inc.” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/08/19/aurinia-pharmaceuticals-inc-auph-downgraded-to-buy-at-vetr-inc-updated-updated.html.
A number of hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada increased its stake in Aurinia Pharmaceuticals by 8.6% in the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 1,341 shares in the last quarter. Jane Street Group LLC bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at approximately $155,000. Cutler Capital Management LLC acquired a new position in shares of Aurinia Pharmaceuticals during the second quarter worth about $184,000. Investment Centers of America Inc. acquired a new position in shares of Aurinia Pharmaceuticals during the second quarter worth about $184,000. Finally, Two Sigma Securities LLC acquired a new position in shares of Aurinia Pharmaceuticals during the first quarter worth about $240,000. 30.29% of the stock is owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
To view Vetr’s full report, visit Vetr’s official website.
What are top analysts saying about Aurinia Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aurinia Pharmaceuticals Inc and related companies.